The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.

Autor: Pizzuti, Laura1, Barba, Maddalena1, Mazzotta, Marco1 marcomazzotta88@gmail.com, Krasniqi, Eriseld1, Maugeri-Saccà, Marcello1, Gamucci, Teresa2, Berardi, Rossana3, Livi, Lorenzo4, Ficorella, Corrado5, Natoli, Clara6, Cortesi, Enrico7, Generali, Daniele8, La Verde, Nicla9, Cassano, Alessandra10, Bria, Emilio10, Moscetti, Luca11, Michelotti, Andrea12, Adamo, Vincenzo13, Zamagni, Claudio14, Tonini, Giuseppe15
Zdroj: Scientific Reports. 7/2/2021, Vol. 11 Issue 1, p1-10. 10p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje